https://ctep.cancer.gov/protocolDevelopment/docs/recist_guideline.pdf

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

WHO CLASSIFICATION OF TUMOURS OF HAEMATOPOIETIC AND LYMPHOID TISSUES , WHO CLASSIFICATION OF TUMOURS OF HAEMATOPOIETIC AND LYMPHOID TISSUES , کتابخانه مرکزی دانشگاه علوم پزشکی تهران

WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues

Immune checkpoints refer to the plethora of inhibitory pathways that are crucial to maintaining self-tolerance. Tumour cells induce immune checkpoints to evade immunosurveillance. This Review discusses the progress in targeting immune checkpoints, the considerations for combinatorial therapy and the potential for additional immune-checkpoint targets.

/pdf/the-blockade-of-immune-checkpoints-in-cancer-immunotherapy-j2cp4ba5s9.pdf

The blockade of immune checkpoints in cancer immunotherapy

12 Pathology and Microbiology, and 13 Diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin's lymphoma, is clinically heterogeneous: 40% of patients respond well to current therapy and have prolonged survival, whereas the remainder succumb to the disease. We proposed that this variability in natural history reflects unrecognized molecular heterogeneity in the tumours. Using DNA microarrays, we have conducted a systematic characterization of gene expression in B-cell malignancies. Here we show that there is diversity in gene expression among the tumours of DLBCL patients, apparently reflecting the variation in tumour proliferation rate, host response and differentiation state of the tumour. We identified two molecularly distinct forms of DLBCL which had gene expression patterns indicative of different stages of B-cell differentiation. One type expressed genes characteristic of germinal centre B cells ('germinal centre B-like DLBCL'); the second type expressed genes normally induced during in vitro activation of peripheral blood B cells ('activated B-like DLBCL'). Patients with germinal centre B-like DLBCL had a significantly better overall survival than those with activated B-like DLBCL. The molecular classification of tumours on the basis of gene expression can thus identify previously undetected and clinically significant subtypes of cancer.

/pdf/distinct-types-of-diffuse-large-b-cell-lymphoma-identified-508avrqemv.pdf

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

We introduce CIBERSORT, a method for characterizing cell composition of complex tissues from their gene expression profiles When applied to enumeration of hematopoietic subsets in RNA mixtures from fresh, frozen and fixed tissues, including solid tumors, CIBERSORT outperformed other methods with respect to noise, unknown mixture content and closely related cell types CIBERSORT should enable large-scale analysis of RNA mixtures for cellular biomarkers and therapeutic targets (http://cibersortstanfordedu/)

/pdf/robust-enumeration-of-cell-subsets-from-tissue-expression-2prfdfkgtp.pdf

Robust enumeration of cell subsets from tissue expression profiles

The CAP-BOP series of induction regimens (cyclophosphamide, doxorubicin, mitox-antrone, procarbazine, bleomycin, vincristine, and prednisone) was administered to 389 patients with advanced aggressive non-Hodgkin’s lymphoma as primary therapy. The overall complete response rates were not different between the three regimens: CB-A (64%), CB-AI (66%), and CB-M (65%). In addition, the 3-year failure-free survivals did not differ by regimen: CB-A (42%), CB-AI (45%), and CB-M (40%). 158 patients with follicular lymphoma were treated with the identical regimens during the same time period. The complete response rates were also similar in the follicular lymphoma patients with CB-A (71%), CB-AI (67%), and CB-M (68%).

Comparison of Front-Line Chemotherapy for Intermediate Grade and Follicular Non-Hodgkin’s Lymphoma Using the CAP-BOP Regimens

Integrative Analysis of Genetic and Tumor Microenvironment Topology to Delineate Prognostic Subtypes in Mantle Cell Lymphoma

Mantle cell lymphoma (MCL) is a rare cancer with diverse management options. Although clinical practice guidelines have become ubiquitous across medicine, the utility of guidelines for MCL management is limited by provider awareness and the lack of a definitive standard of care. We sought to determine whether expert recommendations, delivered as an online decision support tool, impacted practitioners' therapeutic decisions with MCL. Participants were more likely than the experts to select aggressive regimens for both newly diagnosed and relapsed/refractory MCL. After seeing the expert recommendations, participants revealed that the expert opinion impacted their treatment choices in 103 of 365 clinical scenarios, suggesting that online decision support tools may increase the number of clinicians making treatment decisions for patients with MCL that are concordant with expert consensus recommendations.

Clinical impact of Internet-based tools to guide therapeutic decisions for mantle cell lymphoma.

Status of ongoing collaborative efforts.

Lymphomas comprise a diverse array of neoplasms that arise from lymphoid cells. It is now widely accepted that distinct subtypes of lymphoma arise from and correlate with subsets of normal lymphocytes at discrete points in lymphocyte development or maturation. Molecular mechanisms of lymphoma pathogenesis also correlate with lymphoid cell physiology deregulated by identifiable genetic events. Better understanding of the pathogenesis of lymphomas has led to advances in their classification and treatment outcomes. The WHO classification of lymphoid malignancies was updated in 2008 and is based on histologic features, immunophenotype, cytogenetics, and epidemiologic/etiologic factors. The major clinical groupings include non-Hodgkin lymphomas (NHL), Hodgkin lymphomas (HL), and plasma cell neoplasms. Given the intimate relationship between the basic concepts of immunobiology and lymphomagenesis, the first portion of this chapter is devoted to an overview of the fundamentals of the Immune System. The second portion of this chapter discusses the clinical aspects of lymphoma and includes brief descriptions of the common subtypes of lymphoma.

Julie M. Vose

Papers

Comparison of Front-Line Chemotherapy for Intermediate Grade and Follicular Non-Hodgkin’s Lymphoma Using the CAP-BOP Regimens

Integrative Analysis of Genetic and Tumor Microenvironment Topology to Delineate Prognostic Subtypes in Mantle Cell Lymphoma

Clinical impact of Internet-based tools to guide therapeutic decisions for mantle cell lymphoma.

Status of ongoing collaborative efforts.

Overview of the Lymphoid Neoplasms